

# CytRx Corp (CYTR) - Strategic SWOT Analysis Review

<https://marketpublishers.com/r/CC38A35C83AFEN.html>

Date: October 2019

Pages: 40

Price: US\$ 125.00 (Single User License)

ID: CC38A35C83AFEN

## Abstracts

CytRx Corp (CYTR) - Strategic SWOT Analysis Review provides a comprehensive insight into the company's history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company's key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

## Scope

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – GlobalData's summarization of the company's business strategy.

SWOT analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.

## Highlights

CytRx Corp (CytRx) is a clinical stage biopharmaceutical company that focuses on the discovery, development and commercialization of new therapeutics for the treatment of cancer patients. CytRx's lead product doxorubicin is in the late stage of clinical development and finds application in treating relapsed soft tissue melanoma, small-cell lung cancer and other types of cancer with unmet medical needs. The company also has other pipeline products being developed through Linker Activated Drug Release technology platform. CytRx is headquartered in Los Angeles, California, the US.

### CytRx Corp Key Recent Developments

May 15,2019: CytRx reports first quarter 2019 financial results

Mar 29,2019: CytRx corporation reports 2018 financial results

Feb 11,2019: CytRx highlights majority of cancer patients do not have targetable genetic mutations and are therefore candidates for chemotherapy

Dec 21,2018: CytRx announces conclusion of pre-clinical phase for its albumin binding ultra high potency LADR drug candidates and accompanying companion diagnostic

Aug 06,2018: CytRx Reports Second Quarter 2018 Financial Results

## Reasons to Buy

Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.

Identify potential customers and suppliers with this report's analysis of the company's business structure, operations, major products and services and business strategy.

Understand and respond to your competitors' business structure and strategies with GlobalData's detailed SWOT analysis. In this, the company's core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.

Examine potential investment and acquisition targets with this report's detailed insight into the company's strategic, business and operational performance.

**Note:** Some sections may be missing if data is unavailable for the company.

## Contents

### **SECTION 1 - ABOUT THE COMPANY**

CytRx Corp - Key Facts  
CytRx Corp - Key Employees  
CytRx Corp - Key Employee Biographies  
CytRx Corp - Major Products and Services  
CytRx Corp - History  
CytRx Corp - Company Statement  
CytRx Corp - Locations And Subsidiaries  
Head Office  
Other Locations & Subsidiaries

### **SECTION 2 – COMPANY ANALYSIS**

Company Overview  
CytRx Corp - Business Description  
CytRx Corp - SWOT Analysis  
SWOT Analysis - Overview  
CytRx Corp - Strengths  
CytRx Corp - Weaknesses  
CytRx Corp - Opportunities  
CytRx Corp - Threats  
CytRx Corp - Key Competitors

### **SECTION 3 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES**

CytRx Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019  
CytRx Corp, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019  
CytRx Corp, Recent Deals Summary

### **SECTION 4 – COMPANY’S RECENT DEVELOPMENTS**

May 15, 2019: CytRx reports first quarter 2019 financial results  
Mar 29, 2019: CytRx corporation reports 2018 financial results  
Feb 11, 2019: CytRx highlights majority of cancer patients do not have targetable genetic mutations and are therefore candidates for chemotherapy  
Dec 21, 2018: CytRx announces conclusion of pre-clinical phase for its albumin binding

ultra high potency LADR drug candidates and accompanying companion diagnostic

Aug 06, 2018: CytRx Reports Second Quarter 2018 Financial Results

Jun 25, 2018: CytRx joins Russell Microcap Index

Jun 04, 2018: CytRx Launches Centurion BioPharma to Advance LADR Albumin Binding Ultra-High Potency Oncology Drug Candidates

May 08, 2018: CytRx announces First Quarter 2018 Financial Results

May 03, 2018: CytRx Names Eric L. Curtis as Its President and Chief Operating Officer

Apr 18, 2018: CytRx Presents Statistically Significant Breakthrough Data for Its Albumin Binding Ultra High Potency LADR™ Drug Candidates at the American Association for Cancer Research 2018 Annual Meeting

## **SECTION 5 – APPENDIX**

Methodology

About GlobalData

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

CytRx Corp, Key Facts

CytRx Corp, Key Employees

CytRx Corp, Key Employee Biographies

CytRx Corp, Major Products and Services

CytRx Corp, History

CytRx Corp, Subsidiaries

CytRx Corp, Key Competitors

CytRx Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

CytRx Corp, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

CytRx Corp, Recent Deals Summary

## List Of Figures

### LIST OF FIGURES

CytRx Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

CytRx Corp, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

### COMPANIES MENTIONED

Takeda Pharmaceutical Co Ltd

Sanofi

FirstString Research Inc

Seattle Genetics Inc

Pharmacyclics LLC

ZIOPHARM Oncology Inc

CTI BioPharma Corp

AstraZeneca Plc

## I would like to order

Product name: CytRx Corp (CYTR) - Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/CC38A35C83AFEN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CC38A35C83AFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970